Document Type : Original Article
Authors
1
Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt
2
Biochemistry Section, Chemistry Department, Faculty of Science, Tanta University, Egypt
3
Zoology Department, Faculty of Science, Tanta University, Egypt
4
Anatomy and Embryology Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Egypt
Abstract
Sorafenib (SOR) is a potent chemotherapeutic agent used for cancer treatment, however, it has several side effects upon administration on some vital organs. Amygdalin (AMY) is a vitamin B-17 that showed several biological activities as an antioxidant, anti-inflammatory, and anticancer agent. This study was conducted to evaluate the effect of the treatment with a combination of SOR/AMY in Ehrlich ascites carcinoma (EAC)-bearing mice. Twenty-four female CD-1 mice were divided into four groups (n=6) as follows: Group 1 (Gp1) was inoculated with 2 × 106 EAC-cells/mouse and served as a positive control. Gp2, 3, and 4 were inoculated with the same number of EAC-cells as in Gp1, and then injected with AMY (50 mg/Kg/14 days), SOR (10 mg/Kg/14 days), and AMY/SOR intraperitoneal (i.p.), respectively. Bodyweight changes, hematological changes, and antitumor indices were evaluated post-treatments. The results showed that AMY had a slight antitumor effect against EAC-bearing mice. Compared to EAC-bearing mice treated with SOR alone, EAC-bearing mice treated with AMY/SOR showed a decrease in the final body weight, tumor volumes, tumor cells count, totally live and dead tumor cells. Furthermore, treatment with AMY/SOR ameliorated the hematological changes. In summary, co-treatment with AMY enhanced SOR antitumor efficacy in EAC-bearing mice.
Keywords
)
View on SCiNiTO